Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$3.33
-5.1%
$3.71
$2.76
$13.50
$181.17MN/A445,130 shs571,316 shs
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
$5.00
+8.5%
$1.41
$1.09
$2.91
$44.50M1.05130,956 shs302,954 shs
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$6.04
-2.9%
$5.48
$1.97
$22.47
N/A1.39294,879 shs54,968 shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1.77
-6.8%
$1.78
$0.77
$2.27
$176.61M2.311.84 million shs2.86 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
-5.13%-5.40%+10.63%-33.40%-73.53%
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
-0.65%+18.51%+6.47%+31.71%+129.62%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-2.89%-6.21%+6.71%+92.36%-70.42%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-6.84%-3.80%+12.74%+36.15%+60.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alumis Inc. stock logo
ALMS
Alumis
2.6911 of 5 stars
3.60.00.00.00.03.31.3
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
1.5946 of 5 stars
3.41.00.00.00.91.70.6
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
2.2065 of 5 stars
3.51.00.00.02.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alumis Inc. stock logo
ALMS
Alumis
3.22
Buy$22.86586.40% Upside
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
0.00
N/AN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2.71
Moderate Buy$33.83460.15% Upside
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
3.00
Buy$7.00295.48% Upside

Current Analyst Ratings Breakdown

Latest PRAN, SLS, ALMS, and SLN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $7.00
6/13/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
6/13/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
6/10/2025
Alumis Inc. stock logo
ALMS
Alumis
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$18.00
5/15/2025
Alumis Inc. stock logo
ALMS
Alumis
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$26.00 ➝ $25.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$4.00 ➝ $3.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $35.00
4/30/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/22/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/A$5.51 per shareN/A
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
$150K296.67N/AN/A$1.40 per share3.57
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$43.26MN/AN/AN/A$4.48 per shareN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1M176.61N/AN/A$0.13 per share13.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alumis Inc. stock logo
ALMS
Alumis
-$294.23MN/A0.00N/AN/AN/A-406.27%-107.29%8/12/2025 (Estimated)
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
-$6.40M-$0.70N/AN/AN/AN/AN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$45.31M-$1.500.00N/AN/A-260.55%-56.17%-33.96%8/21/2025 (Estimated)
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$30.88M-$0.380.00N/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)

Latest PRAN, SLS, ALMS, and SLN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/15/2025Q2 2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$0.2067N/AN/AN/A$3.38 millionN/A
8/12/2025Q2 2025
Alumis Inc. stock logo
ALMS
Alumis
-$1.11N/AN/AN/A$1.80 millionN/A
8/12/2025Q2 2025
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.0767N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Alumis Inc. stock logo
ALMS
Alumis
-$1.47-$1.82-$0.35-$1.82N/AN/A
5/13/2025Q1 2025
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.1067-$0.07+$0.0367-$0.07N/AN/A
5/8/2025Q1 2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/AN/A
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
N/AN/AN/AN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/AN/AN/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alumis Inc. stock logo
ALMS
Alumis
N/A
3.73
3.73
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
N/A
4.37
N/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/A
8.81
8.81
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/A
4.64
4.64

Institutional Ownership

CompanyInstitutional Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
3.63%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
98.73%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
17.38%

Insider Ownership

CompanyInsider Ownership
Alumis Inc. stock logo
ALMS
Alumis
40.70%
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
38.80%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
4.10%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alumis Inc. stock logo
ALMS
Alumis
N/A54.41 million32.26 millionN/A
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
148.90 millionN/ANot Optionable
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
100N/AN/ANot Optionable
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1099.78 million98.38 millionNot Optionable

Recent News About These Companies

Sellas Flat on Trial Success
Sellas Life Sciences: Tons Of Completed Studies
SELLAS Life Sciences Group, Inc. Common Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alumis stock logo

Alumis NASDAQ:ALMS

$3.33 -0.18 (-5.13%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$3.34 +0.02 (+0.45%)
As of 07/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Alterity Therapeutics stock logo

Alterity Therapeutics NASDAQ:PRAN

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Silence Therapeutics stock logo

Silence Therapeutics NASDAQ:SLN

$6.04 -0.18 (-2.89%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$6.05 +0.01 (+0.18%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

SELLAS Life Sciences Group stock logo

SELLAS Life Sciences Group NASDAQ:SLS

$1.77 -0.13 (-6.84%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.78 +0.00 (+0.28%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.